The journey to develop Encala began when the late Dr. David Yesair, an internationally recognized biochemist, and his family met his daughter’s college roommate, who had cystic fibrosis (CF) and suffered from exocrine pancreatic insufficiency. Dr. Yesair watched his daughter’s roommate struggle to maintain and gain weight despite consuming ever-increasing daily calories. Watching as she succumbed to the disease shortly after graduation deeply affected Dr. Yesair and his family. Dr. Yesair was convinced he could develop a better nutritional solution for patients with EPI and fat-malabsorption, resulting in the birth of Encala, a scientifically based structured lipid to improve fat absorption.
In the clinical study, people with CF and exocrine pancreatic insufficiency took Encala for 1 year and demonstrated improvement in weight and growth in just three months.
Encala is a structured lipid matrix that enables absorption without enzymes. This unique characteristic makes Encala effective for patients with fat-malabsorption, regardless of the cause.
The team at Envara Health is proud to carry Dr. Yesair’s good work on and help patients with fat-malabsorption.